About the Authors

Riva Kovjazin

Affiliation Vaxil BioTherapeutics Ltd., Weizmann Science Park, Nes-Ziona, Israel

Galit Horn

Affiliation Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel

Nechama I. Smorodinsky

Affiliations Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel, The Alec and Myra Marmot Hybridoma Unit, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel

Michael Y. Shapira

Affiliation Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Lior Carmon

lior.carmon@vaxilbio.com

Affiliation Vaxil BioTherapeutics Ltd., Weizmann Science Park, Nes-Ziona, Israel

Competing Interests

The authors have read the journal's policy and have the following conflicts: Lior Carmon is the founder and CEO and Riva Kovjazin, and is a senior scientist of Vaxil BioTherapeutics Ltd., a start-up company which is developing ImMucin, an anti-MUC1 SP therapeutic vaccine against MUC1-positive tumors. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The other authors declare no conflict of interest.

Author Contributions

Conceived and designed the experiments: RK NIS LC. Performed the experiments: RK GH MYS. Analyzed the data: RK GH MYS LC. Contributed reagents/materials/analysis tools: NIS MYS. Wrote the paper: LC. Prepared data: RK GH.